Severe liver enzyme elevations after three years of olanzapine treatment: A case report and review of olanzapine associated hepatotoxicity

被引:43
作者
Ozcanli, Tuba
Erdogan, Ayten
Ozdemir, Samuray
Onen, Baris
Ozmen, Mine
Doksat, Kerem
Sonsuz, Abdullah
机构
[1] Mem Hosp, Dept Child & Adolescent Psychiat, Istanbul, Turkey
[2] Int Hosp, Dept Psychiat, Istanbul, Turkey
[3] Istanbul Univ, Cerrahpasa Med Fac, Dept Psychiat, Istanbul, Turkey
[4] Istanbul Univ, Cerrahpasa Med Fac, Dept Med, Div Hepatol, Istanbul, Turkey
关键词
atypical antipsychotics; hepatotoxicity; liver enzymes; olanzapine; side effects;
D O I
10.1016/j.pnpbp.2006.03.014
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Atypical antipsychotics commonly cause isolated asymptomatic increase in the aminotransferase levels. Among these atypical antipsychotics, mostly transient, asymptomatic increase in hepatic enzymes has been reported with olanzapine, however olanzapine rarely may induce a clinical and/or biological hepatic toxicity. The pathogenesis of olanzapine-associated hepatotoxicity is not well known and is mostly a transient phenomenon. However, substantial and lasting changes may occur and result in symptomatic hepatitis. In the following case report, we report on a 44-year-old female patient diagnosed as Bipolar Disorder Type 1, whose liver enzyme levels increased ten fold of normal ranges during the third year of the olanzapine treatment and returned to the normal levels within three weeks after olanzapine discontinuation. Although significant liver enzyme elevations are uncommon during olanzapine treatment, based on reports of serious hepatotoxicity, controlled and longitudinal research are needed to learn side effects of this drug on liver. Clinicians should be aware of possible hepatotoxic effects of atypical antipsychotics and should monitor the liver enzyme levels whenever they feel necessary. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:1163 / 1166
页数:4
相关论文
共 29 条
[1]  
*AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P273
[2]  
Ananth Jambur, 2004, Ann Clin Psychiatry, V16, P75, DOI 10.1080/10401230490453293
[3]   Safety and effectiveness of olanzapine in monotherapy:: A multivariate analysis of a naturalistic study [J].
Ciudad, A ;
Gutiérrez, M ;
Cañas, F ;
Gibert, J ;
Gascón, J ;
Carrasco, JL ;
Bobes, J ;
Gómez, JC ;
Alvarez, E .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2005, 29 (06) :942-949
[4]   A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder [J].
Conley, RR ;
Mahmoud, R .
AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (05) :765-774
[5]  
Conley RR, 2000, J CLIN PSYCHIAT, V61, P26
[6]   Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course [J].
Cortez-Pinto, H ;
Camilo, ME .
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2004, 18 (06) :1089-1104
[7]  
Doucette DE, 2000, ANN PHARMACOTHER, V34, P1128
[8]  
Dumortier G, 2002, ENCEPHALE, V28, P542
[9]   Management of marked liver enzyme increase during clozapine treatment: A case report and review of the literature [J].
Erdogan, A ;
Kocabasoglu, N ;
Yalug, I ;
Ozbay, G ;
Senturk, H .
INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE, 2004, 34 (01) :83-89
[10]   Relevance of liver enzyme elevations with four different neuroleptics: A retrospective review of 7,263 treatment courses [J].
Gaertner, I ;
Altendorf, K ;
Batra, A ;
Gaertner, HJ .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2001, 21 (02) :215-222